Redox Biology (Jul 2022)

Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells

  • Gilles Rademaker,
  • Yasmine Boumahd,
  • Raphaël Peiffer,
  • Sandy Anania,
  • Tom Wissocq,
  • Maude Liégeois,
  • Géraldine Luis,
  • Nor Eddine Sounni,
  • Ferman Agirman,
  • Naïma Maloujahmoum,
  • Pascal De Tullio,
  • Marc Thiry,
  • Akeila Bellahcène,
  • Vincent Castronovo,
  • Olivier Peulen

Journal volume & issue
Vol. 53
p. 102324

Abstract

Read online

Myoferlin, an emerging oncoprotein, has been associated with a low survival in several cancer types including pancreas ductal adenocarcinoma where it controls mitochondria structure and respiratory functions. Owing to the high susceptibility of KRAS-mutated cancer cells to iron-dependent cell death, ferroptosis, and to the high iron content in mitochondria, we investigated the relation existing between mitochondrial integrity and iron-dependent cell death. We discovered that myoferlin targeting with WJ460 pharmacological compound triggered mitophagy and ROS accumulation culminating with lipid peroxidation and apoptosis-independent cell death. WJ460 caused a reduction of the abundance of ferroptosis core regulators xc- cystine/glutamate transporter and GPX-4. Mitophagy inhibitor Mdivi1 and iron chelators inhibited the myoferlin-related ROS production and restored cell growth. Additionally, we reported a synergic effect between ferroptosis inducers, erastin and RSL3, and WJ460.

Keywords